# OnCo record paper-nct04454437-int-j-cancer-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct04454437-int-j-cancer-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct04454437-int-j-cancer-2023" ;
  schema:name "A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments"@en ;
  schema:description "Published report from the trial registered as NCT04454437, in International journal of cancer (2023), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct04454437-int-j-cancer-2023/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1002/ijc.34424>, <https://pubmed.ncbi.nlm.nih.gov/36621000/>, <https://europepmc.org/article/MED/36621000>, <https://clinicaltrials.gov/study/NCT04454437> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1002/ijc.34424> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Xu B, Ma F, Wang T, et al." ;
  onco:trials <https://onco.cc/trials/nct04454437/> ;
  onco:journals <https://onco.cc/journals/international-journal-of-cancer/> .